Journal
CYTOKINE THERAPIES: NOVEL APPROACHES FOR CLINICAL INDICATIONS
Volume 1182, Issue -, Pages 111-123Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2009.05159.x
Keywords
interleukin (IL-) 1; autoinflammatory diseases; neonatal onset multisystem inflammatory disease (NOMID); chronic inflammatory neurologic, cutaneous and arthritis syndrome (CINCA); deficiency of the IL-1 receptor antagonist (DIRA); NLRP3; IL1RN; IL-1Ra; anakinra; neonatal disorder; genetic disease
Funding
- Intramural NIH HHS [Z01 AR041138-05, Z01 AR041138-06, ZIA AR041138-07] Funding Source: Medline
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041138] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The role of the potent proinflammatory cytokine IL-1 in disease could clinically be investigated with the development of the IL-1 blocking agent anakinra (Kineret (R)), a recombinant IL-1 receptor antagonist. It was first tested in patients with sepsis without much benefit but was later FDA approved for the treatment of patients with rheumatoid arthritis. More recently IL-1 blocking therapies are used successfully to treat a new group of immune-mediated inflammatory conditions, autoinflammatory diseases. These conditions include rare hereditary fever syndromes and pediatric and adult conditions of Still's disease. Recently the FDA approved two additional longer acting IL-1 blocking agents, for the treatment of cryopyrin-associated periodic syndromes (CAPS), an IL-1 dependent autoinflammatory syndrome. The study of autoinflammatory diseases revealed mechanisms of IL-1 mediated organ damage and provided concepts to a better understanding of the pathogenesis of more common diseases such as gout and Type 2 diabetes which show initial promising results with IL-1 blocking therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available